GenomeDx's Decipher GRID and Decipher Tests to be Featured in Multiple Presentations at ASTRO 2016

SAN DIEGO, Sept. 22, 2016 /PRNewswire/ -- GenomeDx Biosciences today announced that eight presentations featuring Decipher Genomics Resource Information Database (Decipher GRID®) and the Decipher® Prostate Cancer Classifier Tests will be presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting being held Sept. 25-28 in Boston.

Oral Presentations:
Title: Identification and Validation of Intrinsic Subtypes of Prostate Cancer
Presentation Number: 6
Date: Sunday, Sept. 25 (3:15 p.m. to 4:45 p.m. EDT)
Room: Grand Ballroom
Session: CT01: Clinical Trials Session
Presenter: Dan Spratt, M.D., University of Michigan

Title: Efficacy of Post-Operative Radiation in a Prostatectomy Cohort Adjusted for Clinical and Genomic Risk
Presentation Number: 233
Date: Tuesday, Sept. 27 (4:15 p.m. to 6:45 p.m. EDT)
Room: 258 A/B/C
Session: Session 30: GU - Prostate Cancer: Post-prostatectomy Radiotherapy
Presenter: Robert Den, M.D., Thomas Jefferson University

Title: A Genomic Classifier Impacts Adjuvant Treatment Decision Making Among Patients With High-Risk Pathology at Radical Prostatectomy: Results From the Multicenter Prospective PRO-IMPACT Study
Presentation Number: 234
Date: Tuesday, Sept. 27 (4:45 p.m. to 6:15 p.m. EDT)
Room: 258 A/B/C
Session: Session 30: GU - Prostate Cancer: Post-prostatectomy Radiotherapy
Presenter: Scott Perrapato, D.O., University of Vermont Medical Center

Title: A 24-Gene Predictor of Response to Postoperative Radiation Therapy in Prostate Cancer
Presentation Number: 235
Date: Tuesday, Sept. 27 (4:45 p.m. to 6:15 p.m. EDT)
Room: 258 A/B/C
Session: Session 30: GU - Prostate Cancer: Post-prostatectomy Radiotherapy
Presenter: Felix Feng, M.D., University of California, San Francisco

Title: The Use of a Biopsy-based Genomic Classifier to Predict the Risk of Distant Metastasis after Definitive Radiation and Short-Course ADT for Intermediate and High Risk Prostate Cancer
Presentation Number: 255
Date: Wednesday, Sept. 28 (7:45 a.m. to 9:00 a.m. EDT)
Room: 205 A/B/C
Session: Session 33: GU - Imaging and Biomarkers of Response and Recurrence
Presenter: Paul Nguyen, M.D., Dana-Farber Cancer Institute

Poster Presentations:
Posters will be available for viewing in Hall C from Sunday, Sept. 25, to Tuesday, Sept. 27, between 10 a.m. and 5 p.m. EDT. Posters will be presented on Monday, Sept. 26 from 5:30 p.m. to 6:45 p.m. EDT.

Title: A Genomic Classifier Impacts Treatment Decision Making Among Patients With Biochemical Recurrence After Radical Prostatectomy: Results From the Multicenter Prospective PRO-IMPACT Study
Presentation Number: 2534
Presenter: Scott Perrapato, D.O., University of Vermont Medical Center

Title: Development and Validation of Genomic Signature That Predicts Androgen Deprivation Therapy Treatment Failure
Presentation Number: 2540
Presenter: Felix Feng, M.D., University of California, San Francisco

Title: The Frequency of Druggable Targets in Localized Prostate Cancer: Initial Analysis From a Commercially Available Genomic Expression Database in Urologic Cancer
Presentation Number: 2611
Presenter: Robert Den, M.D., Thomas Jefferson University

About Decipher® Prostate Cancer Classifier Tests
Our Decipher Prostate Cancer Classifier tests currently include Decipher Biopsy and Decipher Post-Op. These commercially available genomic tests provide an assessment of tumor aggressiveness based on the patient's unique genomic profile. Decipher Biopsy is indicated for men with localized prostate cancer after biopsy diagnosis and Decipher Post-Op is indicated for men after prostate removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups to better determine which patients will likely benefit from additional treatment and which will not, thereby enabling improved decision-making and helping low-risk patients avoid unnecessary treatments that have serious adverse side effects and result in unnecessary costs to the healthcare system. Studies of thousands of patients from leading cancer centers, published in multiple peer-reviewed journals, demonstrate that the Decipher tests can more accurately predict disease aggressiveness than traditional clinical measures, such as PSA and Gleason score. Decipher Post-Op is covered by Medicare and by a number of private payors and preferred provider organizations representing, together with Medicare, about 70% of the approximately 66 million adult men in the United States age 40 or older who are at increased risk of being diagnosed with prostate cancer.

About Decipher GRID®
Our Decipher Genomics Resource Information Database (Decipher GRID) is a genomic expression database that provides a foundation for open and interactive research collaboration and knowledge creation. Decipher GRID is a rapidly growing database that contains genomic profiles of thousands of patient tumors, and constitutes what we believe to be the world's largest shared, clinically-annotated genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases utilizing cloud-based analytics. We believe Decipher GRID gives rise to new opportunities for information technology-enabled genomic solutions and enables us to more rapidly discover, develop, commercialize and drive the adoption of our existing and new genomic tests. Through Decipher GRID, GenomeDx is building a suite of genomic tests in urologic cancer that we believe will allow us to achieve our goals of reducing costs to the healthcare system and improving patient lives, from screening through late-stage therapy.    

About GenomeDx Biosciences
GenomeDx Biosciences uses the power of collaborative genomics to transform the management and treatment of cancer patients. GenomeDx has built Decipher GRID, a large genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than both traditional diagnostic tools and existing genomic tests. GenomeDx's Decipher Biopsy and Decipher Post-Op are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and has offices in San Diego, California.

Learn more at www.GenomeDx.com

SOURCE GenomeDx Biosciences

Related Links

http://www.GenomeDx.com